Penumbra (NYSE:PEN) this week posted fourth-quarter results that beat the revenue consensus on Wall Street but missed earnings estimates. The Alameda, California-based company reported losses of -$24.6 million, or -66¢ per share, on sales of $204 million for the three months ended Dec. 31, 2021, for a sales growth of 22.24% compared with Q4 2020. Get […]
Penumbra
Data shows safety and strong performance for Penumbra’s Indigo CAT RX catheter
Penumbra (NYSE:PEN) announced today that the Cheetah clinical study for its Indigo CAT RX catheter met its primary endpoint. Alameda, California-based Penumbra’s Indigo catheter system demonstrated high rates of blood clot removal, blood flow restoration and myocardial perfusion in conjunction with percutaneous coronary intervention (PCI) in patients with high thrombus burden. The company presented the […]
Penumbra beats The Street in Q3, grows sales 25%
Penumbra (NYSE:PEN) posted third-quarter results this week that beat the overall consensus on Wall Street. The Alameda, California-based company reported profits of $8.85 million, or 24¢ per share, on sales of $190.1 million for the three months ended Sept. 30, for a sales growth of 25.84% compared with Q3 2020. Get the full story on our […]
MedTech 100 roundup: Hot streak comes to slight halt
After several weeks of high-level performance, the medtech industry saw its first dip in a while over the last seven days. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week (Aug. 13) at 117.92 points, marking a –1.2% dip from the 119.41-point tally a week prior […]
Penumbra sales grow 75% in Q2
Penumbra (NYSE:PEN) posted second-quarter results this week that beat the overall consensus on Wall Street. The Alameda, Calif.–based vascular conditions device company reported profits of $9.2 million, or 25¢ per share, on sales of $184.3 million for the three months ended June 30, for a sales growth of 75.3% compared with Q2 2020. Get the full […]
RapidAI launches workflow platform for pulmonary embolism
RapidAI announced today that it launched its mobile and web-based app to aid in the treatment of pulmonary embolism (PE). San Mateo, Calif.-based RapidAI made available the Rapid Workflow for PE, which it designed to align hospital teams on the treatment of patients suspected of having a pulmonary embolism, according to a news release. Rapid […]
FDA clears Penumbra’s Red 62 reperfusion catheter for removing brain blood clots
Penumbra (NYSE:PEN) today said its Red 62 reperfusion catheter has received FDA 510(k) clearance. Alameda, Calif.-based Penumbra designed the catheter to navigate complex distal vessel anatomy and deliver powerful aspiration with its Penumbra Engine to remove blood clots in acute ischemic stroke patients with large vessel occlusions. Get the full story on our sister site, Medical […]
Penumbra slides on Street-beating Q1 results
Penumbra (NYSE:PEN) yesterday posted first-quarter results that beat the earnings consensus on Wall Street and matched sales estimates. The Alameda, Calif.-based company reported profits of $11.836 million, or 32¢ per share, on sales of $169.2 for the three months ended March 31, for a bottom-line gain of 730.6% sales growth of 23.2% compared with Q1 […]
Penumbra beats The Street in Q4 results
Penumbra (NYSE:PEN) posted fourth-quarter results that beat the consensus forecast on Wall Street. The Alameda, Calif.-based company reported profits of $2.6 million, or 10¢ per share, on sales of $166.9 million for the three months ended Dec. 31, 2020, for a bottom-line loss of 071.7% sales growth of 14.89% compared with Q4 2019. Adjusted to exclude […]
FDA: Penumbra recall of some Jet 7 catheters is serious
A Penumbra recall of certain Jet 7 catheters is Class I – the most serious type of recall, the FDA recently said. The recall, which Penumbra originally announced on Dec. 15, 2020, involved more than 30,000 distributed units of its Jet 7 Reperfusion Catheters with Xtra Flex Technology after the company received 14 reports of death related […]
Penumbra on track for higher Q4 revenue
Penumbra (NYSE:PEN) announced today that it expects more than 10% year-over-year sales growth in its fourth-quarter financial results. In its preliminary results, Penumbra expects revenues in the range of $162.5 million to $167.9 million, marking growth of between 12% and 16% when compared to 2019, according to a news release. Within those figures, Alameda Calif.-based Penumbra […]
